Merck vs Dr Reddys Laboratories
MRK and RDY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MRK and RDY compare
Merck grew revenue faster over the last twelve months (4.6% versus 3.2% for Dr Reddys Laboratories).
Dr Reddys Laboratories keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 4.8% at Merck.
Merck pays a dividend yielding 2.3%; Dr Reddys Laboratories does not pay one.
Merck scores higher on the StockData Score (9 against 7 for Dr Reddys Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MRK | RDY |
|---|---|---|
| Size and price | ||
| Market cap | $361B | – |
| Share price | $146.33 | $14.17 |
| Change, 1 year | 68.1% | 5.7% |
| Change, 5 years | 79.3% | 11.8% |
| Beta (5Y) | 0.22 | 0.37 |
| Employees | 75K | – |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 3 | 4 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 117× | – |
| P/S | 5.4× | – |
| P/B | 8.6× | – |
| P/FCF | 22.5× | – |
| PEG | 13.88 | – |
| FCF yield | 4.4% | – |
| Fair value | $42.82 | – |
| Margin of safety | −242% | – |
| Growth | ||
| Revenue growth (TTM) | 4.6% (better) | 3.2% |
| Revenue growth, 5Y average | 9.4% | 12.1% (better) |
| Net income growth (TTM) | −80.7% | −24.2% (better) |
| EPS growth (TTM) | −80.7% | −24.1% (better) |
| EPS growth, 5Y average | 21.2% (better) | 19.9% |
| Profitability | ||
| Gross margin | 73.0% (better) | 52.8% |
| Operating margin | – | 15.0% |
| Net margin | 4.8% | 12.8% (better) |
| FCF margin | 24.1% (better) | 10.0% |
| Return on equity | 7.0% | 12.1% (better) |
| Return on invested capital | – | 9.7% |
| Financial health | ||
| Debt / equity | 1.29 | 0.21 (better) |
| Net debt / EBITDA | – | 0.87 |
| Interest coverage | – | 13.5× |
| Current ratio | 1.32 | 1.80 (better) |
| Altman Z-score | 3.74 | – |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.3% | – |
| Payout ratio | 262% | 15.5% |
| Years of dividend growth | 15 (better) | 0 |
| Dividend growth, 5Y average | 5.8% | 9.9% (better) |
| Buyback yield | 1.2% | – |
| Shareholder yield | 3.5% | – |
| Ownership | ||
| Held by institutions | 80.3% | 15.1% |
| Held by insiders | 0.05% | 13.6% |
| Insider net buying, 12 months | −$72.0M | – |
| Superinvestors holding | 4 | – |
| Short interest, % of float | 1.1% | – |
Go deeper
- MRK stock overview
- MRK income statement
- MRK valuation and score
- RDY stock overview
- RDY income statement
- RDY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.